AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 36054143
Drug: Moxifloxacin (800
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Moxifloxacin (800 mg/day for four days)
Trial: 33028084
Drug: Adjuvant sunitinib
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjuvant sunitinib (50 mg/day; 4 weeks on/2 weeks off)
Trial: 33041039
Drug: 60 mL
RxNorm normalized name: Disposable Nurser 60 mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 60 mL of 1:1 fish:flaxseed oil blend
Trial: 33041039
Drug: 60 mL
RxNorm normalized name: Disposable Nurser 60 mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 60 mL of 1:1 fish:flaxseed oil blend with 200 mg of α‐tocopherol
Trial: 34613358
Drug: Vasopressin and
RxNorm normalized name: Vasopressin and analogues
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vasopressin and steroids
Trial: 34549372
Drug: Family-based behavioral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Family-based behavioral treatment (FBT)
Trial: 35297385
Drug: Sodium bicarbonate
RxNorm normalized name: Sodium Bicarbonate
DrugBank: Sodium bicarbonate (DB01390)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sodium bicarbonate administration in the French dataset (1234 patients, 450 matched)
Trial: 35297385
Drug: Sodium bicarbonate
RxNorm normalized name: Sodium Bicarbonate
DrugBank: Sodium bicarbonate (DB01390)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sodium bicarbonate administration in the North-American dataset (4902 patients, 1238 matched)
Trial: 34848523
Drug: Oestradiol cypionate
RxNorm normalized name: Estradiol Cypionate
DrugBank: Estradiol cypionate (DB13954)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oestradiol cypionate intramuscular (IM) and micronised progesterone oral (PO), in addition to standard of care (SOC)
Trial: 32634068
Drug: Intravenous chemotherapy
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous chemotherapy (cyclophosphamide, doxorubicin, vincristine, and prednisone)
Trial: 35373585
Drug: Bosentan (125
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bosentan (125 mg, twice per day for 3 days)
Trial: 34986562
Drug: Lead toxicity
RxNorm normalized name: lead
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lead toxicity at 400 mg kg‐1
Trial: 34986562
Drug: Lead toxicity
RxNorm normalized name: lead
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lead toxicity at 1200 mg kg‐1
Trial: 34986562
Drug: Control (0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (0 mg kg‐1 lead)
Trial: 32831969
Drug: Conversational therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conversational therapy through VR
Trial: 37464404
Drug: Conventional therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional therapy (CT)
Trial: 34938292
Drug: Chemotherapy on
RxNorm normalized name: Gel-One
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy on day 1 and toripalimab on day 3 (experimental group)
Trial: 34938292
Drug: Chemotherapy and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy and toripalimab on day 1 (control group)
Trial: 35590102
Drug: Transcanalicular laser
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transcanalicular laser dacryocystorhinostomy (TCL‐DCR) with endonasal augmentation after 10 days (Group 2)
Trial: 34853932
Drug: Topical aloe
RxNorm normalized name: Alo Topical Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical aloe vera extract gel applied thrice daily for 2 months
Trial: 34853932
Drug: Low-level laser
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-level laser therapy (LLLT) at 980 nm twice weekly for 2 months
Trial: 35412220
Drug: AMG 986
RxNorm normalized name: AMG 108
DrugBank: AMG 108 (DB05545)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AMG 986 tablet formulation
Trial: 35412220
Drug: AMG 986
RxNorm normalized name: AMG 108
DrugBank: AMG 108 (DB05545)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AMG 986 capsule formulation
Trial: 32949918
Drug: High-protein meal
RxNorm normalized name: bone meal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-protein meal (HP; 30 g protein, 17 g fat, 52 g carbohydrate)
Trial: 32949918
Drug: Low-protein meal
RxNorm normalized name: bone meal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-protein meal (LP; 13 g protein, 25 g fat, 54 g carbohydrate)
Trial: 35980648
Drug: Drug treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drug treatment (silver ion alginate, hydrocolloid dressing, foam dressing)
Trial: 34382590
Drug: Local injection
RxNorm normalized name: Sclerosing agents for local injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Local injection combined with mouth opening training for 2 years
Trial: 34382590
Drug: Local injection
RxNorm normalized name: Sclerosing agents for local injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Local injection of Salvia miltiorrhiza and triamcinolone acetonide, once a week, 8 times a course
Trial: 35764955
Drug: 500 mg
RxNorm normalized name: bran 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 500 mg AEO BID (Long COVID)
Trial: 35764955
Drug: 1000 mg
RxNorm normalized name: bran 1000 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1000 mg AEO (Long COVID)
Trial: 35964170
Drug: Ultrasound (US)
RxNorm normalized name: ULTRASOUND
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ultrasound (US) therapy (15 sessions)
Trial: 35964170
Drug: High-Intensity Laser
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-Intensity Laser Therapy (HILT) (9 sessions)
Trial: 35818187
Drug: Pelvic IMRT
RxNorm normalized name: Sus scrofa renal pelvis preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pelvic IMRT in combination with chemotherapy (Taxol and Carboplatin)
Trial: 35818187
Drug: 3D-CRT in
RxNorm normalized name: isopropyl alcohol
DrugBank: Isopropyl alcohol (DB02325)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3D-CRT in combination with chemotherapy (Taxol and Carboplatin)
Trial: 35218006
Drug: Telephone-based cognitive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Telephone-based cognitive behavioral therapy (Tele-CBT)
Trial: 32956551
Drug: DBBM-CM (without
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DBBM-CM (without immediate implant placement)
Trial: 32956551
Drug: IMPL/DBBM-CM (with
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IMPL/DBBM-CM (with immediate implant placement)
Trial: 35840087
Drug: Ixazomib (3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ixazomib (3 mg, days 1, 8, 15)
Trial: 34369940
Drug: Red wine
RxNorm normalized name: Red wine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Red wine exposure (25 mL rinsed four times a day during bleaching)
Trial: 33565206
Drug: Mesenchymal stromal
RxNorm normalized name: Mesenchymal Stromal Cells
DrugBank: Human Umbilical Cord Mesenchymal Stem Cells (DB15726)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mesenchymal stromal cell (MSC) therapy with early tacrolimus withdrawal
Trial: 33745379
Drug: Intravenous patient-controlled
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous patient-controlled analgesia (IV-PCA)
Trial: 33433720
Drug: Isotretinoin 20
RxNorm normalized name: isotretinoin 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Isotretinoin 20 mg/daily + cryotherapy
Trial: 32880220
Drug: Placebo pills
RxNorm normalized name: placebo Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo pills and patches
Trial: 34601163
Drug: Periarticular multidrug
RxNorm normalized name: camphor
DrugBank: Camphor (DB01744)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Periarticular multidrug injection (PMDI)
Trial: 34325579
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (daily exercise including radio gymnastics and Jianxincao)
Trial: 32292074
Drug: 1.8 mg
RxNorm normalized name: menthol 1.8 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.8 mg liraglutide daily
Trial: 35676450
Drug: TQ‐Z2301 (40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TQ‐Z2301 (40 mg subcutaneously every other week for 24 weeks)
Trial: 32067149
Drug: Low-dose droperidol
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose droperidol (median dose 21 µg/kg)
Trial: 33244559
Drug: Encouragement to
RxNorm normalized name: Wong To Yick
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Encouragement to spend time outdoors for 20-30 minutes daily for two months during summer
Trial: 34651606
Drug: Islatravir 5
RxNorm normalized name: Islatravir
DrugBank: Islatravir (DB15653)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Islatravir 5 mg, once daily for 42 days
Trial: 34651606
Drug: Islatravir 0.25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Islatravir 0.25 mg, once daily for 28 days
Trial: 34651606
Drug: Islatravir 0.75
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Islatravir 0.75 mg, once daily for 28 days
Trial: 34651606
Drug: Islatravir (all
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Islatravir (all doses)
Trial: 35572990
Drug: Endoscopic injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Endoscopic injection sclerotherapy (EIS)
Trial: 35714315
Drug: Augmented therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Augmented therapy in high-risk group
Trial: 35714315
Drug: Augmented therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Augmented therapy in cytogenetic high-risk patients
Trial: 35714315
Drug: Standard therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard therapy in cytogenetic high-risk patients
Trial: 32545655
Drug: CC +
RxNorm normalized name: CC
DrugBank: Cholecalciferol (DB00169)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CC + HF group
Trial: 32545655
Drug: CC +
RxNorm normalized name: CC
DrugBank: Cholecalciferol (DB00169)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CC + MF group
Trial: 33341707
Drug: Low dose
RxNorm normalized name: Low Dose ASA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low dose nab-paclitaxel (LD180) 180 mg/m2
Trial: 36072931
Drug: Sitagliptin plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sitagliptin plus Metformin (100mg sitagliptin and 500mg metformin three times per day)
Trial: 34118179
Drug: Pirepemat 350
RxNorm normalized name: Pirepemat
DrugBank: Pirepemat (DB19165)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pirepemat 350 mg single dose
Trial: 34118179
Drug: Pirepemat 100
RxNorm normalized name: Pirepemat
DrugBank: Pirepemat (DB19165)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pirepemat 100 mg multiple doses (3 times daily for 7 days)
Trial: 34118179
Drug: Pirepemat 250
RxNorm normalized name: Pirepemat
DrugBank: Pirepemat (DB19165)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pirepemat 250 mg multiple doses (3 times daily for 7 days)
Trial: 34118179
Drug: Pirepemat (all
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pirepemat (all doses)
Trial: 35348246
Drug: Prediction model
RxNorm normalized name: reductic acid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prediction model for postoperative severe ALI based on variables including coronary heart disease, cardiopulmonary bypass (CPB) ≥ 257.5 min, left atrium diameter ≥ 35.5 mm, hemoglobin ≤ 139.5 g/L, preCPB OI ≤ 100 mmHg, intensive care unit OI ≤ 100 mmHg, left ventricular posterior wall thickness ≥ 10.5 mm, neutrophilic granulocyte percentage ≥ 0.824.
Trial: 33852204
Drug: Initial triple
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Initial triple therapy with metformin, pioglitazone, and exenatide
Trial: 33852204
Drug: Stepwise conventional
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Stepwise conventional therapy with metformin followed by glipizide and then glargine insulin
Trial: 34675150
Drug: No treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No treatment (Group C)
Trial: 35839791
Drug: Antibiotic prophylaxis
RxNorm normalized name: STONE PROPHYLAXIS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antibiotic prophylaxis (1.5 g cefuroxime, intramuscular in Norway or intravenous in Germany)
Trial: 32638035
Drug: Escitalopram (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Escitalopram (20 mg)
Trial: 35880252
Drug: Closed-loop insulin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Closed-loop insulin delivery with fast-acting insulin aspart
Trial: 35880252
Drug: Standard insulin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard insulin therapy (control group)
Trial: 34726850
Drug: Astra Tech
RxNorm normalized name: carbamide peroxide
DrugBank: Carbamide peroxide (DB11129)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Astra Tech implants (group A)
Trial: 34726850
Drug: Brånemark implants
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Brånemark implants (group B)
Trial: 33419900
Drug: Standard medical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard medical therapy
Trial: 36008143
Drug: Prednisolone (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prednisolone (1 mg/kg for 10 days)
Trial: 32546554
Drug: Cabozantinib 60
RxNorm normalized name: cabozantinib 60 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cabozantinib 60 mg daily as maintenance therapy
Trial: 33921829
Drug: Placebo supplement
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo supplement
Trial: 34010934
Drug: Topical estrogen
RxNorm normalized name: estrogens
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical estrogen therapy (n=12)
Trial: 35543701
Drug: Creatine kinase
RxNorm normalized name: Creatine kinase
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Creatine kinase levels during statin treatment
Trial: 32419559
Drug: Other biotin-containing
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Other biotin-containing supplements recommended by physicians
Trial: 33439250
Drug: Surgical treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Surgical treatment (open reduction and internal fixation using a volar-locking plate)
Trial: 33909355
Drug: Acupuncture plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acupuncture plus medication
Trial: 35357606
Drug: CultActive treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CultActive treatment (A23187 ionophore), 122 MII oocytes treated
Trial: 35357606
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no treatment), 125 MII oocytes
Trial: 35357606
Drug: CultActive treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CultActive treatment (A23187 ionophore)
Trial: 34168003
Drug: Intracerebral administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intracerebral administration of ipilimumab (IPI) 10 mg (cohort-1)
Trial: 34168003
Drug: Intracerebral administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intracerebral administration of ipilimumab (IPI) 5 mg plus nivolumab (NIVO) 10 mg (cohort-2)
Trial: 34168003
Drug: Intravenous administration
RxNorm normalized name: intravenous administration set
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous administration of nivolumab (NIVO) 10 mg, repeated every 2 weeks (max. five administrations)
Trial: 33099227
Drug: Growth hormone
RxNorm normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Growth hormone (1.4 mg every other day)
Trial: 34486272
Drug: Standard antibacterial
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard antibacterial therapy
Trial: 34166834
Drug: GDC-3280 (25–1600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GDC-3280 (25–1600 mg single dose)
Trial: 34166834
Drug: GDC-3280 (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GDC-3280 (200 mg or 275 mg twice daily for 7 days)
Trial: 34166834
Drug: GDC-3280 (400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GDC-3280 (400 mg and 800 mg single dose with food)
Trial: 34166834
Drug: GDC-3280 (400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GDC-3280 (400 mg and 800 mg single dose)
Trial: 34166834
Drug: GDC-3280 (repeat
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GDC-3280 (repeat doses)
Trial: 34166834
Drug: GDC-3280 (single
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GDC-3280 (single doses)
Trial: 35654691
Drug: ACT/control (cetuximab
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ACT/control (cetuximab + irinotecan‐based chemotherapy)
Trial: 32384122
Drug: Encala™ treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Encala™ treatment
Trial: 36262803
Drug: Neoadjuvant hormone
RxNorm normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Neoadjuvant hormone therapy (NHT) with anastrozole for at least six months (menopausal patients) or anastrozole with subcutaneous goserelin acetate every 12 weeks for at least six months (premenopausal women).
Trial: 36262803
Drug: Neoadjuvant chemotherapy
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neoadjuvant chemotherapy (NCT) with a standard institutional regimen based on anthracyclines and taxanes.
Trial: 34119409
Drug: Intervention bundle
RxNorm normalized name: oxymetazoline
DrugBank: Oxymetazoline (DB00935)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intervention bundle (vitamin C sprays, peppermint water mouthwash, lip moisturiser)
Trial: 34119409
Drug: Placebo interventions
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo interventions (saline sprays, 40 °C water mouthwash, wetting lips with water)
Trial: 33368499
Drug: Rabeprazole 20
RxNorm normalized name: RABEprazole 20 mg oral delayed release tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rabeprazole 20 mg/day
Trial: 35732396
Drug: Treatment Group
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment Group 1 - smart electronic toothbrush, educational booklet
Trial: 35551845
Drug: 30 mg
RxNorm normalized name: agar 30 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 mg of cannabidiol
Trial: 32151503
Drug: Modified constraint-induced
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Modified constraint-induced movement therapy (mCIMT), 1 hour therapy sessions for 14 consecutive days, normal arm constrained for 6 hours per day.
Trial: 32038017
Drug: Oral solutions
RxNorm normalized name: Oral Film
DrugBank: Sodium citrate (DB09154)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral solutions enriched with maltodextrin
Trial: 32993815
Drug: Oral placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral placebo and omeprazole 20 mg single dose 6 h before RAI therapy followed by oral placebo and omeprazole 20 mg daily for 3 days.
Trial: 32417348
Drug: Dose‐escalated IMRT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dose‐escalated IMRT
Trial: 35397249
Drug: SWITCH group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SWITCH group (monotherapy with either FGA or SGA)
Trial: 35397249
Drug: STAY group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: STAY group (combination treatment of FGA and SGA)
Trial: 32696522
Drug: Luspatercept (0.2-1.25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Luspatercept (0.2-1.25 mg/kg, subcutaneously once every 3 weeks)
Trial: 33166594
Drug: 38 %
RxNorm normalized name: dextrose 38 % in water
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 38 % silver diamine fluoride (SDF) solution followed by placebo varnish
Trial: 35988083
Drug: Olfactory training
RxNorm normalized name: BOS TAURUS OLFACTORY BULB
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Olfactory training (daily sessions for 3 months)
Trial: 35500264
Drug: Daily liraglutide
RxNorm normalized name: Liraglutide
DrugBank: Liraglutide (DB06655)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Daily liraglutide
Trial: 33637061
Drug: MOVE group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MOVE group treatment (MOVE-G)
Trial: 33637061
Drug: MOVE individual
RxNorm normalized name: chondroitin sulfates
DrugBank: Chondroitin sulfate (DB09301)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MOVE individual treatment (MOVE-I)
Trial: 33637061
Drug: Both treatments
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both treatments (MOVE-G and MOVE-I)
Trial: 34049452
Drug: Oral cannabis
RxNorm normalized name: Medical Cannabis
DrugBank: Medical Cannabis (DB14009)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral cannabis (10 mg THC)
Trial: 34049452
Drug: Blood THC
RxNorm normalized name: BLOOD TEST
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Blood THC concentrations after inhalation
Trial: 33982406
Drug: Topical 1%
RxNorm normalized name: fluoride topical 1% topical gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical 1% cyclopentolate hydrochloride
Trial: 33982406
Drug: Topical 1%
RxNorm normalized name: fluoride topical 1% topical gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical 1% cyclopentolate hydrochloride combined with 2.5% phenylephrine
Trial: 33776997
Drug: Galantamine 8
RxNorm normalized name: galantamine 8 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Galantamine 8 mg daily for 4 weeks